TARA Protara Therapeutics Inc: Earnings per share for the trailing year

The quotes provided below demonstrate the EPS dynamics of Protara Therapeutics (TARA), whose operations are associated with risks stemming from a small patient population and a dependence on investments. The business is currently focusing on verifying the efficacy of cell-based therapies for lymphatic and bladder pathologies, with the indicator standing at 4.00. Particular attention is paid to strict adherence to temperature controls during the transportation of high-cost drugs.
TARA (Protara Therapeutics Inc): analytical breakdowns and indicator data

When constructing a long-term portfolio, stability of earnings per share serves as a key screening filter. This indicator measures the percentage change in EPS over a rolling twelve-month period, allowing for an assessment of the business's actual capitalization efficiency. For Protara Therapeutics (TARA), which invests in alliances for the treatment of rare pathologies, this metric reflects the financial return on joint research. By analyzing the rolling year-over-year EPS growth chart, an investor can filter out news noise from fundamental trends.